These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


236 related items for PubMed ID: 23572142

  • 1. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study.
    Majumdar SR, Morin SN, Lix LM, Leslie WD.
    Osteoporos Int; 2013 Sep; 24(9):2493-8. PubMed ID: 23572142
    [Abstract] [Full Text] [Related]

  • 2. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
    Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM.
    Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
    [Abstract] [Full Text] [Related]

  • 3. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD, Martineau P, Bryanton M, Lix LM.
    Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
    [Abstract] [Full Text] [Related]

  • 4. Fracture prediction from repeat BMD measurements in clinical practice.
    Leslie WD, Brennan-Olsen SL, Morin SN, Lix LM.
    Osteoporos Int; 2016 Jan; 27(1):203-10. PubMed ID: 26243362
    [Abstract] [Full Text] [Related]

  • 5. Risk-equivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry.
    Leslie WD, Shevroja E, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D.
    Osteoporos Int; 2018 Mar; 29(3):751-758. PubMed ID: 29392355
    [Abstract] [Full Text] [Related]

  • 6. Discriminative ability of trabecular bone score over bone mineral density for vertebral and fragility fracture in patients treated with long-term and low-dose glucocorticoid.
    Lee KA, Kim J, Kim HJ, Kim HS.
    Int J Rheum Dis; 2021 Aug; 24(8):1053-1060. PubMed ID: 34184827
    [Abstract] [Full Text] [Related]

  • 7. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
    Segaud N, Legroux I, Hazzan M, Noel C, Cortet B.
    Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
    [Abstract] [Full Text] [Related]

  • 8. High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice.
    Leslie WD, Majumdar SR, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA, Manitoba Bone Density Program.
    Osteoporos Int; 2012 Jan; 23(1):391-7. PubMed ID: 21365460
    [Abstract] [Full Text] [Related]

  • 9. A comparative study of using non-hip bone density inputs with FRAX®.
    Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA, Manitoba Bone Density Program.
    Osteoporos Int; 2012 Mar; 23(3):853-60. PubMed ID: 22008881
    [Abstract] [Full Text] [Related]

  • 10. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma.
    Dam TT, Harrison S, Fink HA, Ramsdell J, Barrett-Connor E, Osteoporotic Fractures in Men (MrOS) Research Group.
    Osteoporos Int; 2010 Aug; 21(8):1341-9. PubMed ID: 19816753
    [Abstract] [Full Text] [Related]

  • 11. Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density.
    Hayashi K, Yamamoto M, Murakawa Y, Yamauchi M, Kaji H, Yamaguchi T, Sugimoto T.
    Osteoporos Int; 2009 Nov; 20(11):1889-94. PubMed ID: 19387764
    [Abstract] [Full Text] [Related]

  • 12. Impact of spine-hip discordance on fracture risk assessment and treatment qualification in Canada: the Manitoba BMD registry.
    Leslie WD, Morin SN, Lix LM, Binkley N.
    Arch Osteoporos; 2020 Jun 08; 15(1):85. PubMed ID: 32514615
    [Abstract] [Full Text] [Related]

  • 13. Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study.
    Chen W, Johnson KM, FitzGerald JM, Sadatsafavi M, Leslie WD.
    Arch Osteoporos; 2018 Oct 29; 13(1):116. PubMed ID: 30374631
    [Abstract] [Full Text] [Related]

  • 14. Performance of FRAX in clinical practice according to sex and osteoporosis definitions: the Manitoba BMD registry.
    Leslie WD, Majumdar SR, Morin SN, Lix LM, Schousboe JT, Ensrud KE, Johansson H, McCloskey EV, Kanis JA.
    Osteoporos Int; 2018 Mar 29; 29(3):759-767. PubMed ID: 29404625
    [Abstract] [Full Text] [Related]

  • 15. Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome.
    Phan V, Blydt-Hansen T, Feber J, Alos N, Arora S, Atkinson S, Bell L, Clarson C, Couch R, Cummings EA, Filler G, Grant RM, Grimmer J, Hebert D, Lentle B, Ma J, Matzinger M, Midgley J, Pinsk M, Rodd C, Shenouda N, Stein R, Stephure D, Taback S, Williams K, Rauch F, Siminoski K, Ward LM, Canadian STOPP Consortium.
    Osteoporos Int; 2014 Feb 29; 25(2):627-37. PubMed ID: 23948876
    [Abstract] [Full Text] [Related]

  • 16. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar 29; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 17. FRAX for fracture prediction shorter and longer than 10 years: the Manitoba BMD registry.
    Leslie WD, Majumdar SR, Morin SN, Lix LM, Johansson H, Oden A, McCloskey EV, Kanis JA.
    Osteoporos Int; 2017 Sep 29; 28(9):2557-2564. PubMed ID: 28593449
    [Abstract] [Full Text] [Related]

  • 18. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat.
    Ont Health Technol Assess Ser; 2006 Sep 29; 6(20):1-180. PubMed ID: 23074491
    [Abstract] [Full Text] [Related]

  • 19. Frequency of normal bone measurement in postmenopausal women with fracture: a registry-based cohort study.
    Binkley N, Morin SN, Martineau P, Lix LM, Hans D, Leslie WD.
    Osteoporos Int; 2020 Dec 29; 31(12):2337-2344. PubMed ID: 32778934
    [Abstract] [Full Text] [Related]

  • 20. Change in Bone Mineral Density Is an Indicator of Treatment-Related Antifracture Effect in Routine Clinical Practice: A Registry-Based Cohort Study.
    Leslie WD, Majumdar SR, Morin SN, Lix LM.
    Ann Intern Med; 2016 Oct 04; 165(7):465-472. PubMed ID: 27428723
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.